The call & mid afternoon update First the call.
There were more analysts questions than we have heard in a long time.
The question around partnerships was asked. It was phrased clear & with little wiggle room.
The answer was qualified by " we can not preict when"
They also DID address the change of the 90 day window, by stating both the ":precision promise & $5 million grant" came late in the game.
They did mention multiple discussions with multiple stakeholders & working towards the best overall long term opportunitiy for Pelareorep. Across a broader range of applications.
My commentary on that.
The details are in the details. Some may argue " what negotiations & with who"
They said very clearly in a public recorded form " they are" not " we hope to," be in discussions.
subtle but huge difference.
Assuming there becomes a total buy- out, that information & negotiations trail would become part of presentation to shareholders.
Board meeting have minutes & even " in camera" items like negotiations are a matter of record.
so any argument of scam, fraud etc is a 100% red herring.
saying that, we know they are in partership discussions. " buy out " never discussed & wont be until/ if that /gets closer to reality.
Again, first document of any buyout negotiations is a NDA.
keeping in mind that every statement they make is vetted by lawyers.
todays message could have discussed many other things.
CAR-t, the ongoing Incyte trial, the mm trial not discussed.
The China partership. Not discussed.
The $17 million was discussed in financials. No details.
Matt worked hard at providing laser focus on 3 points.
ironically I can not remember the 3 points.
I think , getting ready for panc phase 3, the ever increasing MOA data & the recent biomarker results.?
It was significantly different than previous conference calls.
question , why?
One coukd argue either side.
Too much data confuses?
Most forgotten items could be dead the water or one signature away of a B.D. Partnership.
The onky thing I know for sure. Using comparables in the biotech market. Onc is extremely undervalued.
Matt did mention a board meeting yesterday.
would like to be a fly on that wall.
great weekend all